Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases
Table 2
Patient 1: laboratory findings and cumulative number of transfused blood products at different timepoints.
Test unit (normal range)
Day 1 of induction
Day 11 (P-LD rising)
Day 23 (before 1st plasma exchange)
Day 52 (last plasma exchange)
Day 63 (cardiac tamponade)
Day 81 (discharge)
Day 98 (the last BM sample)
B-Hb g/dL (11.7–15.5)
11.9
12.1
NAA
7.4
7.5
9.3
9.9
B-WBC x109/L (3.4–8.2)
3.9
0.1
0.1
0.8
0.4
5.7
6.0
B-PLTs x109/L (150–360)
83
44
122
14
18
67
29
B-neutrophils x109/L (1.5–6.7)
0.39
<0.05
<0.05
0.43
0.14
4.73
4.31
P-CRP mg/L (<4)
<4
28
411
216
266
57
33
P-Hb mg/L (<50)
2167
376
186
87
77
P-LD U/L (115–235)
201
513
1566
660
353
181
175
P-Haptog g/L (0.29–2.0)
4.53
1.46
0.61
P-Ferritin μg/L (15–125)
11
>16500
1609
1016
1918
2303
P-creatinine μmol/L (50–90)
45
40
49
21
22
29
36
P-ALT U/L (<35)
<9
20
52
42
13
58
31
P-bilirubin μmol/L (<20)
7
5
5
7
29
14
11
P-TnI mg/L (<45)
10
68
136
99
45
18
Cumulative number of RBC units
0
0
0
7
12
14
14
Cumulative number of PLT units
0
7
17
39
57
71
77
Abbreviations: ALT, alanine transferase; B, blood; BM, bone marrow; CRP, C-reactive protein; Hb, hemoglobin; LD, lactate dehydrogenase; NAA, not able to analyze; P, plasma; PLTs, platelets; RBC, red blood cell; TnI, troponine I; WBC, white blood cell.
